Articles About Blood Disorders Universal Data Collection (UDC)
* These CDC scientific articles are listed in order of date published, from 2005 to present.
The link will take you to a short summary of the article. The full article is available to subscribers of the publication’s service.
Evaluation of CDC’s Hemophilia Surveillance Program – Universal Data Collection (1998-2011) and Community Counts (2011–2019), United States.
MMWR Surveill Summ. 2020;69(5):1–18.
Schieve LA, Byams VR, Dupervil B, et al.
Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity.
Res Pract Thromb Haemost. 2020;4(6):1035–1045.
Wang M, Recht M, Iyer NN, Cooper DL, Soucie JM.
US Hemophilia Treatment Center Network. Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease.
Am J Hematol. 2020;95(1):10–17.
Abe K, Dupervil B, O’Brien SH, et al.
The Frequency of Joint Hemorrhages and Procedures in Non-severe Hemophilia A versus B.
Blood Advances 2018;2:2136–44.
Soucie JM, Monahan PE, Kulkarni R, Konkle BA, Mazepa MA; U.S. Hemophilia Treatment Center Network.
Risk factors associated with invasive orthopedic interventions in males with hemophilia enrolled in the Universal Data Collection (UDC) program from 2000–2010.
Tobase P, Lane H, Siddiqi A-E-A, et al.
Relevance of Abusive Head Trauma to Intracranial Hemorrhages and Bleeding Disorders.
Anderst J, Carpenter S, Presley R, et al.
Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding.
Srivaths LV, Zhang QC, Byams VR, et al.
Prophylaxis use among males with haemophilia B in the United States.
Ullman M, Zhang QC, Grosse SD, Recht M, Soucie JM, Hemophilia Treatment Center Network Investigators.
The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States.
Soucie JM, Grosse SD, Siddiqi A-E-A, et al.
Prophylaxis usage, bleeding rates and joint outcomes of hemophilia 1999–2010: A surveillance project.
Manco-Johnson MJ, Soucie JM, Gill JC.
Complications of haemophilia in babies (first two years of life): A report from the Centers for Disease Control and Prevention Universal Data Collection System.
Kulkarni, Presley RJ, Lusher JM, et al.
Declining trends in invasive orthopedic interventions for people with hemophilia enrolled in the Universal Data Collection program (2000–2010).
Tobase P, Lane H, Siddiqi AEA, Ingram-Rich R, Ward RS.
Men with severe hemophilia in the United States: birth cohort analysis of a large national database.
Mazepa MA, Monahan PE, Baker JR, Riske BK, Soucie JM, US Hemophilia Treatment Center Network.
Evaluation of von Willebrand factor phenotypes and genotypes in hemophilia A patients with and without identified F8 mutations.
Journal of Thrombosis and Haemostasis 2015;13(6):1036–42.
Boylan B, Rice AS, De Staercke C, et al.
Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening. American Journal of Hematology 2015;90(10):871–6.
Miller CH, Rice AS, Boylan B, et al.
Improving the performance of factor VIII inhibitor tests in hemophilia A.
Thrombosis Research 2015;136(6):1047–1048.
A public health approach to the prevention of inhibitors in hemophilia.
American Journal of Preventive Medicine 2014;47(5):669–673.
Soucie JM, Miller CH, Kelly FM, Oakley M, Brown DL, Kucab P.
Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: A Universal Data Collection database analysis.
Carpenter SL, Soucie JM, Presley, et al.
Impact of inhibitors on hemophilia A mortality in the United States.
Am J Hematol. 2015;90(5):400–5.
Walsh CE, Soucie JM, Miller CH, the United States Hemophilia Treatment Center Network.
Association of overweight and obesity with the use of self and home-based infusion therapy among haemophilic men.
Ullman M, Zhang QC, Brown D, Grant A, Soucie JM, Hemophilia Treatment Center Network Investigators.
Females with FVIII and FIX deficiency have reduced joint range of motion.
Am J Hematol. 2014;89:831–836.
Sidonio RF, Mili FD, Li T, et al.
Functional outcomes following ankle arthrodesis in males with hemophilia: analyses using the CDC’s Universal Data Collection surveillance project.
Lane H, Siddiqi AEA, Ingram-Rich R, et al.
Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database.
Puetz J, Soucie JM, Kemptom CL, Monahan PE, Hemophilia Treatment Center Network (HTCN) Investigators.
Severe and moderate haemophilia A and B in US females.
Di Michele DM, Gibb C, Lefkowitz JM, Ni Q, Gerber LM, Ganguly A.
Similarity in Joint Function Limitation in Type 3 Von Willebrand Disease and Moderate Haemophilia A.
Sood S, Cuker A, Wang C, et al.
Evidence for the Transmission of Parvovirus B19 in Patients with Bleeding Disorders Treated with Plasma-derived Factor Concentrates in the Era of Nucleic Acid Test (NAT) Screening.
Soucie JM, De Staercke C, Monahan PE, et al.
Prevalence of Clinical Hip Abnormalities in Hemophilia A and B: An Analysis of the UDC Database.
Kelly D, Zhang QC, Soucie JM, Manco-Johnson M, et al.
The Effect of Secondary Prophylaxis versus Episodic Treatment on the Range of Motion of Target Joints in Patients with Hemophilia.
British Journal of Haematology 2013;161(3):424–433.
Gupta S, Siddiqi A, Soucie JM, et al.
Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database.
Carpenter SL, Soucie JM, Sterner S, Presley, Hemophilia Treatment Center Network (HTCN) Investigators.
Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States.
British Journal of Haematology 2011;152(2):211–216.
Witmer C, Presley R, Kulkarni R, Soucie JM, Manno CS, Raffini L.
Insurance, Home Therapy, and Prophylaxis in U.S. Youth with Severe Hemophilia.
Baker JR, Riske B, Voutsis M, Cutter S, Presley R.
Physical Functioning in Boys with Hemophilia in the U.S.
Monahan PE, Baker JR, Riske B, Soucie JM.
Surveillance of female patients with inherited bleeding disorders in United States haemophilia treatment centres.
Haemophilia 2011;17(Suppl 1):6–3.
Byams VR, Kouides p, Kulkarni R, et al.
The longitudinal effect of body adiposity on joint mobility in young males with hemophilia A.
Soucie JM, Wang C, Siddiqi A, et al.
Bleeding disorders in neonates.
Kenet G, Chan AKC, Soucie JM, Kulkarni R.
High school completion rates among men with hemophilia.
American Journal of Preventative Medicine 2010;38(4 Suppl):S489–S494.
Drake JH, Soucie JM, Cutter SC, Forsberg AD, Baker JR, Riske B.
Bleeding Symptoms and Laboratory Correlation in Patients with Severe von Willebrand Disease.
Metjian AD, et al.
Sites of Initial Bleeding Episodes, Mode of Delivery and Age of Diagnosis in Babies with Haemophilia Diagnosed Before the Age of 2 Years.
Kulkarni R, et al.
Septic Arthritis in Males with Haemophilia.
Ashrani AA, Key NS, Soucie JM, Duffy N, Forsyth A, Geraghty S.
Incidence of Inhibitors in a Cohort of 838 Males with Hemophilia A Previously Treated with Factor VIII Concentrates.
Journal of Thrombosis and Haemostasis 2006;4(12):2576–2581.
Kempton CL, Soucie JM, Abshire TC.
Parvovirus B19 Transmission by High-Purity Factor VIII Concentrate
Wu C, et al.
Human Parvovirus B19 in young males with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation.
Soucie JM, Siwak EB, Hooper WC, Evatt BL, Hollinger FB.
Joint range of motion among young males with hemophilia: Prevalence and risk factors.
Soucie JM, Cianfrini C, Janco RL, et al.
Blood Safety Monitoring Among Persons with Bleeding Disorders—United States, May 1998–June 2002.
MMWR Morbidity and Mortality Weekly Report 2003;51(51):1152–1154.
Hollinger FB, Kirtava A, Oakley M, Soucie M, Evatt B.
Search a database of articles that have been published by CDC authors within the National Center on Birth Defects and Developmental Disabilities from 1990 to present.